AnaptysBio, Inc. (NASDAQ:ANAB) Receives $46.22 Consensus PT from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $46.22.

A number of research analysts have commented on the stock. Wells Fargo & Company began coverage on shares of AnaptysBio in a research note on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target for the company. Stifel Nicolaus started coverage on AnaptysBio in a research note on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective for the company. BTIG Research started coverage on AnaptysBio in a report on Monday, February 26th. They set a “buy” rating and a $55.00 price objective for the company. Wedbush raised shares of AnaptysBio from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $20.00 to $34.00 in a report on Tuesday, March 12th. Finally, Piper Sandler began coverage on shares of AnaptysBio in a report on Friday, February 16th. They set an “overweight” rating and a $80.00 price target for the company.

AnaptysBio Price Performance

Shares of ANAB stock opened at $25.68 on Wednesday. AnaptysBio has a one year low of $13.36 and a one year high of $27.50. The stock has a fifty day moving average price of $22.90 and a 200 day moving average price of $20.92. The stock has a market cap of $701.58 million, a P/E ratio of -4.22 and a beta of -0.32.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The company had revenue of $9.01 million during the quarter, compared to analysts’ expectations of $3.28 million. Equities research analysts anticipate that AnaptysBio will post -6.17 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other news, CEO Daniel Faga sold 145,940 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the sale, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the sale, the chief executive officer now owns 752,087 shares in the company, valued at $17,132,541.86. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The disclosure for this sale can be found here. In the last 90 days, insiders sold 153,940 shares of company stock worth $3,513,773. 33.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of the business. Fisher Asset Management LLC grew its holdings in AnaptysBio by 0.7% during the 4th quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after acquiring an additional 500 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in AnaptysBio in the first quarter valued at about $38,000. China Universal Asset Management Co. Ltd. increased its holdings in AnaptysBio by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 2,051 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 3,381 shares during the period. Finally, Algert Global LLC boosted its holdings in AnaptysBio by 40.2% during the third quarter. Algert Global LLC now owns 16,530 shares of the biotechnology company’s stock worth $297,000 after buying an additional 4,740 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.